MedTherapy Slashes Gene Therapy Costs

MedTherapy is set to transform the accessibility of advanced genetic treatments by significantly reducing their associated costs and manufacturing durations. The company's CEO, Dr. Bikesh Verma, emphasized that gene therapy represents a future of cures rather than mere symptom management, aiming to correct diseases at their genetic root.

A groundbreaking advancement by MedTherapy is the acceleration of gene therapy production. While typically taking weeks or months, the company claims it can now manufacture certain gene therapies in a single day. Technological improvements have reportedly slashed both manufacturing time and cost by around 70%.

MedTherapy's strategy involves developing a broad platform technology rather than a single product, intending to support numerous global partners. This initiative aims to position India as a leading global manufacturing center for gene therapy through international collaborations.

The company is actively engaged in developing therapies for blood cancers and solid tumors, with a particular focus on expanding CAR-T therapy's application beyond blood cancers into solid tumors. This effort is being pursued in partnership with international collaborators, including those in the United States.

Dr. Verma explained that the high cost of gene therapy stems from intensive research, lack of mass production, and manufacturing complexity, often involving modified viruses. He also noted that a shortage of skilled manpower in both India and the US presents a constraint for scaling production.

MedTherapy attributes its cost-reduction strategy to technological advancements and collaborations, not compromises in quality. The company believes that technology and collaborative spirit are the key drivers for making these life-changing therapies more affordable.